Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.71 |
| ▸ | HTT | P42858 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CCR9 | P51686 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | CCR2 | P41597 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ITGA1 | P56199 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2533283 | 0.85 | LMNA (0.64) | LMNAHTTMAPTTP53KMT2A | |
| SCHEMBL2528724 | 0.85 | LMNA (0.64) | LMNAHTTMAPTTP53KMT2A | |
| SCHEMBL2528312 | 0.85 | LMNA (0.67) | LMNAHTTMAPTTP53KMT2A | |
| SCHEMBL2528982 | 0.85 | ITGA1 (0.69) | LMNAHTTMAPTTP53KMT2A | |
| SCHEMBL12032387 | 0.85 | LMNA (0.64) | LMNAHTTMAPTTP53KMT2A | |
| SCHEMBL27346407 | 0.84 | KMT2A (0.64) | LMNAHTTKMT2AALDH1A1 | |
| SCHEMBL2535989 | 0.84 | LMNA (0.73) | LMNAHTTMAPTTP53KMT2A | |
| SCHEMBL14371154 | 0.84 | LMNA (0.65) | LMNAHTTMAPTTP53KMT2A | |
| SCHEMBL12032434 | 0.84 | LMNA (0.62) | LMNAHTTMAPTTP53KMT2A | |
| SCHEMBL15354035 | 0.83 | LMNA (0.79) | LMNAHTTMAPTTP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160068479-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMECEUTICALS INC (US) | 2016-03-10 | — | — | US | disclosed |
| US-9035096-B2 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068479-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | LMNA 3548/4885HTT 4358/4885MAPT 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.